Cover Image

Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry

Few data exist on health-related quality of life (QoL) in patients with metastatic pancreatic cancer (mPC) receiving first-line chemotherapy (Awad L ZE, Mesbah M Boston, MA. Applying survival data methodology to analyze quality of life data, in Mesbah M, Cole BF, Ting Lee M-L (eds): Statistical Meth...

Full description

Saved in:
Bibliographic Details
Main Authors: Batran, Salah-Eddin al- (Author) , Hofheinz, Ralf-Dieter (Author) , Reichart, Alexander (Author) , Pauligk, Claudia (Author) , Schönherr, Caroline (Author) , Schlag, Rudolf (Author) , Siegler, Gabriele (Author) , Dörfel, Steffen (Author) , Koenigsmann, Michael (Author) , Zahn, Mark-Oliver (Author) , Schubert, Jörg (Author) , Aldaoud, Ali (Author) , Höffkes, Heinz-Gert (Author) , Schulz, Holger (Author) , Hahn, Lars (Author) , Uhlig, Jens (Author) , Blau, Wolfgang (Author) , Stauch, Martina (Author) , Weniger, Jörg (Author) , Wolf, Martin (Author) , Jacobasch, Lutz (Author) , Bildat, Stephan (Author) , Wehmeyer, Jürgen (Author) , Homann, Nils (Author) , Trojan, Jörg (Author) , Waidmann, Oliver (Author) , Fietz, Thomas (Author) , Feustel, Hans-Peter (Author) , Groschek, Matthias (Author) , Wierecky, Jan (Author) , Waibel, Karin (Author) , Mahlmann, Stefan (Author) , Schwindel, Uwe (Author) , Peters, Uwe (Author) , Schuch, Gunter (Author) , Pink, Daniel (Author) , Eschenburg, Henning (Author) , Wörns, Marcus-A. (Author) , Harich, Hans-Detlev (Author) , Weikersthal, Ludwig Fischer von (Author) , Däßler, Klaus-Ulrich (Author) , Behringer, Dirk M. (Author) , Messmann, Helmut (Author) , Kretzschmar, Albrecht (Author) , Gallmeier, Eike (Author) , Forstbauer, Helmut (Author) , Kunzmann, Volker (Author) , Papke, Jens (Author) , Büchner-Steudel, Petra (Author) , Vehling-Kaiser, Ursula (Author) , Springfeld, Christoph (Author) , Vogel, Arndt (Author) , Ettrich, Thomas J. (Author) , Schaaf, Marina (Author) , Hausen, Gerrit zur (Author) , Götze, Thorsten (Author)
Format: Article (Journal)
Language:English
Published: 15 March 2021
In: International journal of cancer
Year: 2021, Volume: 148, Issue: 6, Pages: 1478-1488
ISSN:1097-0215
DOI:10.1002/ijc.33336
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/ijc.33336
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.33336
Get full text
Author Notes:Salah-Eddin Al-Batran, Ralf-Dieter Hofheinz, Alexander Reichart, Claudia Pauligk, Caroline Schönherr, Rudolf Schlag, Gabriele Siegler, Steffen Dörfel, Michael Koenigsmann, Mark-Oliver Zahn, Jörg Schubert, Ali Aldaoud, Heinz-Gert Höffkes, Holger Schulz, Lars Hahn, Jens Uhlig, Wolfgang Blau, Martina Stauch, Jörg Weniger, Martin Wolf, Lutz Jacobasch, Stephan Bildat, Jürgen Wehmeyer, Nils Homann, Jörg Trojan, Oliver Waidmann, Thomas Fietz, Hans-Peter Feustel, Matthias Groschek, Jan Wierecky, Karin Waibel, Stefan Mahlmann, Uwe Schwindel, Uwe Peters, Gunter Schuch, Daniel Pink, Henning Eschenburg, Marcus-A. Wörns, Hans-Detlev Harich, Ludwig Fischer von Weikersthal, Klaus-Ulrich Däßler, Dirk M. Behringer, Helmut Messmann, Albrecht Kretzschmar, Eike Gallmeier, Helmut Forstbauer, Volker Kunzmann, Jens Papke, Petra Büchner-Steudel, Ursula Vehling-Kaiser, Christoph Springfeld, Arndt Vogel, Thomas J. Ettrich, Marina Schaaf, Gerrit zur Hausen, Thorsten Oliver Götze
Description
Summary:Few data exist on health-related quality of life (QoL) in patients with metastatic pancreatic cancer (mPC) receiving first-line chemotherapy (Awad L ZE, Mesbah M Boston, MA. Applying survival data methodology to analyze quality of life data, in Mesbah M, Cole BF, Ting Lee M-L (eds): Statistical Methods for Quality of Life Studies: Design, Measurements and Analysis. Kluwer Academic Publishers 2002). The QOLIXANE study is a prospective, noninterventional, multicenter substudy of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer (PARAGON) registry, which evaluated QoL in patients with mPC receiving first-line gemcitabine and nab-paclitaxel chemotherapy in real-life setting. QoL was prospectively measured via EORTC QLQ-C30 questionnaires at baseline and every month thereafter. Therapy and efficacy parameters were prospectively collected. Main objectives were the rate of patients without deterioration of Global Health Status/QoL (GHS/QoL) at 3 and 6 months. Six hundred patients were enrolled in 95 German study sites. Median progression-free survival was 5.9 months (95% confidence interval [CI], 5.2-6.3). Median overall survival (OS) was 8.9 months (95% CI, 7.9-10.2), while median time to deterioration of GHS/QoL was 4.7 months (95% CI, 4.0-5.6). With a baseline GHS/QoL score of 46 (SD, 22.8), baseline QoL of the patients was severely impaired, in most cases due to loss in role functioning and fatigue. In the Kaplan-Meier analysis, 61% and 41% of patients had maintained GHS/QoL after 3 and 6 months, respectively. However, in the QoL response analysis, 35% and 19% of patients had maintained (improved or stable) GHS/QoL after 3 and 6 months, respectively, while 14% and 9% had deteriorated GHS/QoL with the remaining patients being nonevaluable. In the Cox regression analysis, GHS/QoL scores strongly predicted survival with a hazard ratio of 0.86 (P < .0001). Patients with mPC have poor QoL at baseline that deteriorates within a median of 4.7 months. Treatment with gemcitabine and nab-paclitaxel is associated with maintained QoL in relevant proportions of patients. However, overall, results remain poor, reflecting the aggressive nature of the disease.
Item Description:First published: 10 October 2020
Gesehen am 14.09.2021
Physical Description:Online Resource
ISSN:1097-0215
DOI:10.1002/ijc.33336

Similar Items